Splenic histiocytic sarcoma: report of one case and review of literature
10.3760/cma.j.cn115356-20210116-00017
- VernacularTitle:脾组织细胞肉瘤一例并文献复习
- Author:
Xinxin XU
1
;
Yong YU
;
Xiangdong YANG
;
Junhua LU
;
Chong LI
;
Lixiang YAN
Author Information
1. 天津中医药大学第一附属医院血液内科 300381
- Keywords:
Spleen;
Histiocytic sarcoma;
Drug therapy, combination
- From:
Journal of Leukemia & Lymphoma
2021;30(6):353-356
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To improve awareness of the diagnosis and treatment of splenic histiocytic sarcoma.Methods:The clinical data of one patient with splenic histiocytic sarcoma who was admitted to First Teaching Hospital of Tianjin University of Traditional Chinese Medicine in July 2020 were retrospectively analyzed, and the relevant domestic and foreign literature was reviewed.Results:The patient was diagnosed as splenic histiocytic sarcoma by histopathological and immunohistochemical examinations. The methylprednisolone combined with cyclosporine was ineffective. The patient received a total splenectomy, followed by chemotherapy with VECD and CHOP regimens. The patient's condition was stable during the 5-month follow-up after the operation. The result of bone puncture showed that there was no infiltration of histocytic sarcoma, and hematological remission was obtained.Conclusions:Splenic histocytic sarcoma is a highly malignant tumor with insidious onset, unclear pathogenesis, and lack of specificity in clinical manifestations and imaging examinations. The diagnosis depends on pathological biopsy and immunohistochemistry, and needs to be differentiated from other malignant tumors of lymphoid hematopoietic tissue. At present, there is no best treatment for splenic histiocytic sarcoma, and most patients have a poor prognosis.
